The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511616-24-00

Acronym

KT-US-499-0150

Enrollment

Registered

2024-05-29

Start date

2024-12-06

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and/or Refractory B-cell Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026